Truenorth screen

True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Job Openings at True North Therapeutics

Description Location
Director, Program Management South San Francisco, CA, US
Medical Director South San Francisco, CA, US
Sr. Scientist, Inflammation South San Francisco, CA, US